Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$140.03 USD

140.03
3,600,461

-5.20 (-3.58%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $139.64 -0.39 (-0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Company News for Dec 9, 2022

Companies in The News Are: COP, NVDA, MRNA, RENT

Company News for Dec 8, 2022

Companies in The News Are: UAL, BKNG, MRNA, CVNA

Andrew Rocco headshot

Bucking the Trend: 3 Stocks Showing Stellar Relative Strength this Week

Market pullbacks can offer a treasure trove of ideas in the form of relative strength.

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

Shaun Pruitt headshot

Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?

Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.

Shaun Pruitt headshot

Buy this Medical Sector Pioneer Stock

Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.

Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.

The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.

Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.

Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal

Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.

Company News for Nov 15, 2022

Companies in The News Are: MSFT, MRNA, BBWI, TSN

Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update

Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook

Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.

Moderna (MRNA) Lags Q3 Earnings Estimates

Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More

Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.

Alkermes (ALKS) Q3 Earnings Match Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 0% and 8.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.

Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View

Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales.